Bristol Myers Squibb Company $BMY Stock Sold by HighTower Advisors LLC

HighTower Advisors LLC decreased its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,116,928 shares of the biopharmaceutical company’s stock after selling 9,793 shares during the period. HighTower Advisors LLC owned about 0.05% of Bristol Myers Squibb worth $69,696,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Financial Freedom LLC purchased a new position in shares of Bristol Myers Squibb in the third quarter worth about $26,000. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $27,000. Addison Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $32,000. Groupe la Francaise boosted its holdings in Bristol Myers Squibb by 562.9% in the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 501 shares during the period. Finally, Arlington Trust Co LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter valued at approximately $35,000. 76.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on BMY. Citigroup reissued a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Daiwa Securities Group raised their price target on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Morgan Stanley reduced their price target on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research report on Friday, October 30th. Leerink Partners lowered Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $73.00 to $59.00 in a research note on Monday, October 5th. Finally, Truist Financial set a $70.00 price objective on Bristol Myers Squibb in a report on Friday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus target price of $65.46.

Read Our Latest Analysis on Bristol Myers Squibb

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $59.49 on Thursday. The stock’s 50 day simple moving average is $61.65 and its two-hundred day simple moving average is $60.41. The stock has a market cap of $121.61 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.32 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. Bristol Myers Squibb Company has a fifty-two week low of $45.26 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. During the same period last year, the company posted $1.63 EPS. Bristol Myers Squibb’s revenue was up 6.9% on a year-over-year basis. As a group, analysts expect that Bristol Myers Squibb Company will post 6.46 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is currently 55.88%.

Key Bristol Myers Squibb News

These are some of the BMY news items that stood out recently:

  • Positive Sentiment: Bristol Myers reported that KarXT reduced hallucinations and delusions in patients with psychosis associated with Alzheimer’s disease in two Phase 3 ADEPT studies. The findings add evidence for a potential use of the drug beyond schizophrenia, although the newly presented results are preliminary. Reuters article
  • Positive Sentiment: BMY is sponsoring an early-stage collaboration with Erasca to test a drug combination for a genetically defined form of pancreatic cancer. The Phase 1/2 trial offers pipeline potential, but it is an early research program and not a near-term revenue driver. Yahoo Finance article
  • Negative Sentiment: Shares broke below their 200-day moving average, a technical signal that can encourage selling and add pressure in the near term. American Banking News article

Insider Activity

In other news, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director owned 30,279 shares of the company’s stock, valued at $1,916,963.49. This trade represents a 11.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is currently owned by insiders.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

See Also

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.